These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 12162700)

  • 21. Setting sights on the treatment of ocular angiogenesis using antisense oligonucleotides.
    Henry SP; Marcusson EG; Vincent TM; Dean NM
    Trends Pharmacol Sci; 2004 Oct; 25(10):523-7. PubMed ID: 15380936
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The future of antisense oligonucleotides in the treatment of respiratory diseases.
    Ulanova M; Schreiber AD; Befus AD
    BioDrugs; 2006; 20(1):1-11. PubMed ID: 16573347
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multitargeted approach using antisense oligonucleotides for the treatment of asthma.
    Allakhverdi Z; Allam M; Guimond A; Ferrari N; Zemzoumi K; Séguin R; Paquet L; Renzi PM
    Ann N Y Acad Sci; 2006 Oct; 1082():62-73. PubMed ID: 17145927
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Toxicology of antisense therapeutics.
    Jason TL; Koropatnick J; Berg RW
    Toxicol Appl Pharmacol; 2004 Nov; 201(1):66-83. PubMed ID: 15519609
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Local administration of antisense phosphorothioate oligonucleotides to the c-kit ligand, stem cell factor, suppresses airway inflammation and IL-4 production in a murine model of asthma.
    Finotto S; Buerke M; Lingnau K; Schmitt E; Galle PR; Neurath MF
    J Allergy Clin Immunol; 2001 Feb; 107(2):279-86. PubMed ID: 11174194
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antisense therapy against CCR3 and the common beta chain attenuates allergen-induced eosinophilic responses.
    Gauvreau GM; Boulet LP; Cockcroft DW; Baatjes A; Cote J; Deschesnes F; Davis B; Strinich T; Howie K; Duong M; Watson RM; Renzi PM; O'Byrne PM
    Am J Respir Crit Care Med; 2008 May; 177(9):952-8. PubMed ID: 18244953
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potential therapeutic application of antisense oligonucleotides in the treatment of ocular diseases.
    Danis RP; Henry SP; Ciulla TA
    Expert Opin Pharmacother; 2001 Feb; 2(2):277-91. PubMed ID: 11336586
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro toxicology and pharmacokinetics of antisense oligonucleotides.
    Crooke RM
    Anticancer Drug Des; 1991 Dec; 6(6):609-46. PubMed ID: 1772572
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Antisense oligonucleotides: a new therapeutic approach].
    Guinot P; Temsamani J
    Pathol Biol (Paris); 1998 May; 46(5):347-54. PubMed ID: 9769897
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cell membranes as barriers for the use of antisense therapeutic agents.
    Jääskeläinen I; Urtti A
    Mini Rev Med Chem; 2002 Aug; 2(4):307-18. PubMed ID: 12370052
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oligonucleotide therapy of allergic asthma.
    Metzger WJ; Nyce JW
    J Allergy Clin Immunol; 1999 Aug; 104(2 Pt 1):260-6. PubMed ID: 10452739
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Application of antisense oligonucleotides for gene functionalization and target validation.
    Bennett CF; Cowsert LM
    Curr Opin Mol Ther; 1999 Jun; 1(3):359-71. PubMed ID: 11713801
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antitumor mechanisms of systemically administered epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck.
    Thomas SM; Ogagan MJ; Freilino ML; Strychor S; Walsh DR; Gooding WE; Grandis JR; Zamboni WC
    Mol Pharmacol; 2008 Mar; 73(3):627-38. PubMed ID: 18025070
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers.
    Amantana A; Iversen PL
    Curr Opin Pharmacol; 2005 Oct; 5(5):550-5. PubMed ID: 16087398
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Liver as a target for oligonucleotide therapeutics.
    Sehgal A; Vaishnaw A; Fitzgerald K
    J Hepatol; 2013 Dec; 59(6):1354-9. PubMed ID: 23770039
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An RNA external guide sequence ribozyme targeting human interleukin-4 receptor alpha mRNA.
    Dreyfus DH; Matczuk A; Fuleihan R
    Int Immunopharmacol; 2004 Aug; 4(8):1015-27. PubMed ID: 15222976
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is there a future for cell-penetrating peptides in oligonucleotide delivery?
    Lee SH; Castagner B; Leroux JC
    Eur J Pharm Biopharm; 2013 Sep; 85(1):5-11. PubMed ID: 23958313
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PRO-051, an antisense oligonucleotide for the potential treatment of Duchenne muscular dystrophy.
    Hammond SM; Wood MJ
    Curr Opin Mol Ther; 2010 Aug; 12(4):478-86. PubMed ID: 20677099
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modulation of lipoprotein metabolism by antisense technology: preclinical drug discovery methodology.
    Crooke RM; Graham MJ
    Methods Mol Biol; 2013; 1027():309-24. PubMed ID: 23912993
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-inflammatory activity of inhaled IL-4 receptor-alpha antisense oligonucleotide in mice.
    Karras JG; Crosby JR; Guha M; Tung D; Miller DA; Gaarde WA; Geary RS; Monia BP; Gregory SA
    Am J Respir Cell Mol Biol; 2007 Mar; 36(3):276-85. PubMed ID: 16990616
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.